Pharmaceuticals Japan

Japan Migraine Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Japan Migraine Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $517.6 Mn Placeholder estimate
Estimate 2025 $563.1 Mn 6.4% of the global market
Projected 2034 $1.20 Bn 113.6% Adds $639.9 Mn over 9 forecast years
CAGR 2025–2034 8.8% Faster than 53% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Japan is 6.44% of the global market.
  • In APAC, the largest is China at $742.9 Mn.
  • Fastest growing: India at 11.3% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$639.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Migraine Drugs Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $517.6 Mn — —
2025 (base) $563.1 Mn +$45.5 Mn —
2026 (forecast) $612.7 Mn +$49.6 Mn +8.8%
2027 (forecast) $666.6 Mn +$53.9 Mn +18.4%
2028 (forecast) $725.2 Mn +$58.7 Mn +28.8%
2029 (forecast) $789.1 Mn +$63.8 Mn +40.1%
2030 (forecast) $858.5 Mn +$69.4 Mn +52.5%
2031 (forecast) $934.0 Mn +$75.5 Mn +65.9%
2032 (forecast) $1.02 Bn +$82.2 Mn +80.5%
2033 (forecast) $1.11 Bn +$89.4 Mn +96.4%
2034 (forecast) $1.20 Bn +$97.3 Mn +113.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Japan Migraine Drugs Market Analysis at a glance
Market size, 2025$563.1 Mn placeholder estimate
Forecast, 2034$1.20 Bn placeholder estimate
Growth (CAGR), 2025–20348.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, use and end user (see all)
Key playersPfizer Inc., AbbVie Inc., Teva Pharmaceutical, Eli Lilly and Company, Amgen Inc. and 1 more (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials11 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Migraine Drugs Market Analysis Executive Summary

Migraine drugs stop or prevent migraine attacks, including newer CGRP-blocking medicines and triptans.

Key segments of the migraine Drugs market include drug class (CGRP Antibodies, Gepants and Triptans) and use (Acute Treatment and Prevention).

Bar chart: Japan Migraine Drugs market size, 2024–2034, placeholder estimates. $517.6 Mn in 2024, $563.1 Mn in 2025 and $1.20 Bn in 2034, 8.8% CAGR.
Japan Migraine Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Migraine Drugs Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the migraine Drugs market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the migraine Drugs market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the migraine Drugs market.

Competitive Landscape for Migraine Drugs Market in Japan

The migraine Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Migraine Drugs Market in Japan

Migraine Drugs in Japan: rules, payment and research

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 11 studies on Migraine Drugs that are recruiting, active or about to start in Japan.⁠[3]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for migraine Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Migraine Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Migraine Drugs in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Migraine Drugs market in Japan?
Placeholder estimate: about $563.1 Mn in 2025, rising to about $1.20 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Migraine Drugs market in Japan growing?
Placeholder estimate: about 8.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Migraine Drugs market report cover?
The report splits the market by drug class (CGRP Antibodies, Gepants, Triptans, Ditans and more), use (Acute Treatment, Prevention) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Migraine Drugs market?
Key players include Pfizer Inc., AbbVie Inc., Teva Pharmaceutical, Eli Lilly and Company, Amgen Inc. and Lundbeck.
What is driving the Migraine Drugs market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the migraine Drugs market.
Who regulates Migraine Drugs in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on Migraine Drugs are running in Japan?
11 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on Migraine Drugs?
PubMed lists 60 papers on Migraine Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Japan

See all

Related on brain and nerves and pain

See the topic